Abbott announced one-year results from the VERITAS study showing its Amulet 360 Left Atrial Appendage Occluder achieved a 96.3% complete closure rate of the left atrial appendage in patients with non-valvular atrial fibrillation. The device also demonstrated a low incidence of ischemic stroke and systemic embolism, with over 98% of patients stroke-free after one year. Designed as an alternative to long-term blood thinners, Amulet 360 features enhanced design for better adaptability and sealing. These results support its potential as a safer stroke prevention option for AFib patients.
Abbott Laboratories (ABT) trades at USD 106.56 on Pluang as of Nov 02, 2026 21:13 WIB, showing a modest 0.30% gain for the day. The company’s strong market presence is reflected in its $183.77 billion market cap and a dividend yield of 2.37%. This steady trading performance complements the news of Abbott’s Amulet 360 device demonstrating high closure rates and low stroke incidence in patients with atrial fibrillation.
